RVMDW (STOCKS)

    Revolution Medicines, Inc. Warrant

    Change: —
    Prev close: —
    Company Information
    Exchange
    XNAS
    Sector
    Industry
    CEO
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    Employees
    809
    P/E (TTM)
    P/B (TTM)
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Dec 2025)
    Revenues $0.00
    Nonoperating Income/Loss $51.07M
    Operating Expenses $1.18B
    Research and Development $987.33M
    Other Operating Expenses $195.04M
    Operating Income/Loss -$1.18B
    Income/Loss From Continuing Operations After Tax -$1.13B
    Income/Loss From Continuing Operations Before Tax -$1.13B
    Income Tax Expense/Benefit $0.00
    Income Tax Expense/Benefit, Current $0.00
    Income Tax Expense/Benefit, Deferred $0.00
    Net Income/Loss -$1.13B
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$1.13B
    Net Income/Loss Available To Common Stockholders, Basic -$1.13B
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$5.95
    Diluted Earnings Per Share -$5.95
    Basic Average Shares 190,129,154
    Diluted Average Shares 190,129,154
    Assets $2.35B
    Current Assets $2.08B
    Noncurrent Assets $279.47M
    Fixed Assets $33.19M
    Intangible Assets $55.80M
    Other Non-current Assets $190.48M
    Liabilities $723.21M
    Current Liabilities $290.42M
    Accounts Payable $64.62M
    Other Current Liabilities $225.81M
    Noncurrent Liabilities $432.79M
    Equity $1.63B
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $1.63B
    Liabilities And Equity $2.35B
    Net Cash Flow From Operating Activities -$897.74M
    Net Cash Flow From Operating Activities, Continuing -$897.74M
    Net Cash Flow From Investing Activities $118.06M
    Net Cash Flow From Investing Activities, Continuing $118.06M
    Net Cash Flow From Financing Activities $621.52M
    Net Cash Flow From Financing Activities, Continuing $621.52M
    Net Cash Flow -$158.16M
    Net Cash Flow, Continuing -$158.16M
    Comprehensive Income/Loss -$1.13B
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$1.13B
    Other Comprehensive Income/Loss $1.92M